Document Detail


MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
MedLine Citation:
PMID:  24297376     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: One-third of rheumatoid arthritis (RA) patients treated with biological therapy show lack of response. The use of predictive biomarkers to identify responders to treatment may provide guidance in optimising treatment strategies and reduce unnecessary side effects and costs.
OBJECTIVE: To test the ability of myeloid-related proteins (MRP)8/14 protein complexes, an endogenous TLR-4 receptor agonist, to predict and monitor response to biologics in RA patients.
METHODS: 170 RA patients treated with adalimumab (n=86), infliximab (n=60) or rituximab (n=24) were categorised into clinical responders (n=123) and non-responders (n=47). MRP8/14 serum complexes were measured at baseline, and 4 and 16 weeks after initiation of treatment and related to response outcome.
RESULTS: Before initiation of treatment, responders showed significantly higher MRP8/14 protein complex levels compared with non-responders in each prospective cohort (p=0.010, p=0.001 and p<0.001, respectively). Logistic regression analysis showed that having high MRP8/14 baseline levels increased the odds of being a responder by 3.3 up to 55. In responders to adalimumab or infliximab treatment, MRP8/14 levels decreased after 4 weeks of treatment by 46% and 60% and after 16 weeks by 61% and 68%, respectively. In contrast, MRP8/14 levels were stable in non-responders. In patients treated with rituximab, MRP8/14 levels decreased by 59% after 16 weeks in responders and increased by 89% after 16 weeks in non-responders.
CONCLUSION: Serum concentrations of MRP8/14 protein complex are a promising biomarker to predict response to biological therapy in active RA patients at baseline and could be used to monitor response to treatment across different mechanisms of action.
Authors:
Ivy Y Choi; Danielle M Gerlag; Marieke J Herenius; Rogier M Thurlings; Carla A Wijbrandts; Dirk Foell; Thomas Vogl; Johannes Roth; Paul P Tak; Dirk Holzinger
Related Documents :
23034426 - Variables of host response in saliva of patients with periodontitis: a pilot study.
24099056 - The spectrum of epileptic syndromes with fixation off sensitivity persisting in adult l...
24438496 - Mobile biofeedback of heart rate variability in patients with diabetic polyneuropathy: ...
2838166 - Induction of in vitro tumoricidal activity in alveolar macrophages and monocytes from p...
22356196 - Elevated serum levels of interleukin 21 are associated with disease severity in psorias...
24133356 - Chronic kidney disease, hemodynamic instability, and endoscopic high-risk appearance ar...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-12-2
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  -     ISSN:  1468-2060     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2013 Dec 
Date Detail:
Created Date:  2013-12-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Quantitative syndesmophyte measurement in ankylosing spondylitis using CT: longitudinal validity and...
Next Document:  New insights into Chlamydia and arthritis. Promise of a cure?